Innovations in the Treatment of Urothelial Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 364
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recurrence rates for bladder cancer or upper-tract TCC remain high, with as many as 60% of patients requiring repeat treatments within 24 months, despite treatment with intravesical BCG or other chemotherapy regimens. While most tumors comprise forms of non-muscle-invasive bladder cancer (NMIBC), nearly one in four progress to muscle-invasive disease, with an increased risk of progressing to metastatic disease. Despite initially high response rates to treatment, recurrence rates for bladder cancer remain high. These high rates of tumor recurrence and risk of progression may explain why mortality rates for bladder cancer have decreased far less than for those observed among patients with other cancers, such as prostate, breast, lung, and colon cancer. In addition, tumor recurrence is invariably associated with the significant impairment of quality of life (QoL)-related outcomes.
With the advent of immunotherapy and other innovative treatments, the last decade has brought new hope to patients with urothelial cancer. With many novel diagnostic tools such as MRI, and with new biomarkers and treatments on the horizon, there is increased optimism that we will change the trajectory of this disease in the near future. The goal of this Special Issue is to highlight several novel avenues in the diagnosis and treatment of urothelial cancer.
Prof. Dr. Gilad E. Amiel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
